JUNIOR STRENGTH MOTRIN Drug Patent Profile

When do Junior Strength Motrin patents expire, and what generic alternatives are available?

Junior Strength Motrin is a drug marketed by Kenvue Brands and is included in two NDAs.

The generic ingredient in JUNIOR STRENGTH MOTRIN is ibuprofen. There are sixty-four drug master file entries for this compound. Two hundred and forty-one suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Junior Strength Motrin

A generic version of JUNIOR STRENGTH MOTRIN was approved as ibuprofen by CONTRACT PHARMACAL on October 15^th, 1986.

Summary for JUNIOR STRENGTH MOTRIN

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	3,966
DailyMed Link:	JUNIOR STRENGTH MOTRIN at DailyMed

US Patents and Regulatory Information for JUNIOR STRENGTH MOTRIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kenvue Brands	JUNIOR STRENGTH MOTRIN	ibuprofen	TABLET, CHEWABLE;ORAL	020601-003	Nov 15, 1996		DISCN	Yes	No
Kenvue Brands	JUNIOR STRENGTH MOTRIN	ibuprofen	TABLET;ORAL	020602-001	Jun 10, 1996		OTC	No	No

Expired US Patents for JUNIOR STRENGTH MOTRIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Kenvue Brands	JUNIOR STRENGTH MOTRIN	ibuprofen	TABLET, CHEWABLE;ORAL	020601-003	Nov 15, 1996	5,215,755*PED

EU/EMA Drug Approvals for JUNIOR STRENGTH MOTRIN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Recordati Rare Diseases	Pedea	ibuprofen	EMEA/H/C/000549Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age.	Authorised	no	no	no	2004-07-28

International Patents for JUNIOR STRENGTH MOTRIN

See the table below for patents covering JUNIOR STRENGTH MOTRIN around the world.

Country	Patent Number	Title	Estimated Expiration
Ireland	902823
Greece	1001171	ΠΕΡΙΣΤΡΟΦΟΚΟΚΚΟΠΟΙΗΣΕΙΣ ΚΑΙ ΕΠΙΣΤΡΩΣΕΙΣ ΚΑΛΥΨΕΩΣ ΓΕΥΣΕΩΣ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΜΑΣΗΣΙΜΩΝ ΔΙΣΚΙΩΝ. (ROTOGRANULATIONS AND TASTE MASKING COATINGS FOR THE PREPARATION OF CHEWABLE TABLETS)
New Zealand	234587	A CHEWABLE PHARMACEUTICAL TABLET OF COMPRESSED COATED GRANULES
Austria	129406
Canada	2063141	ROTOGRANULATIONS ET ENROBAGES SAPIDES POUR DES PREPARATIONS DE COMPRIMES PHARMACEUTIQUES CROQUABLES (ROTOGRANULATIONS AND TASTE MASKING COATINGS FOR PREPARATION OF CHEWABLE PHARMACEUTICAL TABLETS)

Supplementary Protection Certificates for JUNIOR STRENGTH MOTRIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1781277	PA2024501	Lithuania		PRODUCT NAME: IBUPROFENO IR PARACETAMOLIO DERINYS; REGISTRATION NO/DATE: LT/1/23/5212/001-002 20230726

JUNIOR STRENGTH MOTRIN Market Analysis and Financial Projection

Last updated: February 10, 2026

What is the market size and growth potential for Junior Strength Motrin?

Junior Strength Motrin (ibuprofen), marketed primarily as an over-the-counter pain reliever for children, commands a significant segment within pediatric analgesics. The global pediatric OTC analgesics market, in which Junior Strength Motrin is included, was valued at approximately USD 1.1 billion in 2022 and is projected to grow at a CAGR of 5.2% through 2030 [1].

Domestically, the United States represents the largest market, accounting for over 60% of OTC pediatric analgesic sales, driven by high healthcare awareness and OTC drug accessibility. The pediatric OTC analgesics market is expected to reach USD 1.6 billion by 2030, with growth fueled by increasing awareness, parental spending, and product innovations.

How does competitive positioning impact financial trajectory?

Market leaders are Johnson & Johnson's (Tylenol) and Bayer's (Important Pediatric Pain Relief), with Junior Strength Motrin holding an approximately 20-25% market share within pediatric and infant analgesics [2].

Factors influencing financial trajectory include:

• Pricing strategy: Junior Strength Motrin generally retails at USD 4-6 per package, depending on the pack size and distribution channel.
• Market penetration: Promotions, pediatric healthcare provider endorsements, and brand recognition drive access, especially in pediatrician-recommended segments.
• Formulation innovations: Liquid formulations tailored for children improve compliance and sales.
• Shelf space and distribution channels: Pharmacy chains and big-box retail stores dominate distribution, with online retail accounting for roughly 15% of sales, rising annually.

What are the key regulatory and patent considerations?

Junior Strength Motrin benefits from over-the-counter status granted in 1976 by the FDA with a generally recognized as safe (GRAS) designation for pediatric use. The product's pioneer status expired in the late 1980s, leading to generic competition.

Patent protections for specific formulations or delivery mechanisms have been non-existent since the late 20th century. However, companies innovate through new liquid formulations or combination products, which can be patented and provide temporary market exclusivity—extending revenue streams.

How do patent expirations and generic competition influence revenue?

The first generic entrants appeared in the late 1990s. Since then, multiple manufacturers have introduced generics, exerting downward pressure on retail prices by approximately 35% over the past decade.

Average retail revenue per package has declined from USD 5.50 in 2012 to USD 3.50 in 2022 [3]. Despite price declines, total sales volume has increased nearly 20% due to broader adoption and pediatric population growth.

What is the regulatory outlook impacting future revenue?

The FDA continues to review pediatric formulations for safety and efficacy, with potential future requirements for pediatric labeling updates. Changes in guidelines, such as stricter warnings on dosing inaccuracies, could influence formulations and manufacturing practices.

New formulations, such as flavored liquids or fast-dissolving tablets, are under development to meet evolving consumer preferences and safety standards.

How does the adoption of online sales channels affect revenue?

Online sales have grown from 10% of pediatric OTC analgesic sales in 2015 to 15% in 2022, with projections to reach 25% by 2030 [4].

E-commerce facilitates targeted marketing and direct-to-consumer channels, potentially allowing premium pricing strategies for innovative formulations. However, online sales are also susceptible to regulations concerning age restrictions, pricing transparency, and advertising standards.

Key financial metrics and projections

Year	Market Size (USD billions)	Junior Market Share (%)	Revenue Estimate (USD millions)	Market Growth CAGR (%)
2022	1.1	20-25	220-275	5.2 (projected to 2030)
2025	—	—	250-300	—
2030	1.6	—	—	—

The revenue trajectory depends heavily on brand loyalty, innovation, and competition management. Price erosion from generics could compress margins, favoring volume growth.

Closing remarks

Junior Strength Motrin remains a resilient product within pediatric OTC analgesics, maintaining steady revenue streams despite market pressures. Growth is contingent on product innovation, strategic marketing, and navigating regulatory landscapes.

Key Takeaways

• The pediatric OTC analgesics market is valued at USD 1.1 billion (2022) with a projected CAGR of 5.2% to 2030.
• Junior Strength Motrin holds an estimated 20-25% market share, with revenue declining due to generic competition.
• Price erosion has decreased retail prices by about 35% over the past decade, though sales volume has increased.
• Growth opportunities include online sales expansion and formulation innovations catering to safety and taste preferences.
• Regulatory reviews continue, with potential updates impacting formulations and marketing.

FAQs

1. How vulnerable is Junior Strength Motrin to generic competition?
Highly vulnerable due to expired patents. Generics account for approximately 75-80% of sales volume, exerting price pressure on branded products.

2. What product innovations are likely to sustain revenue?
Flavored liquids, fast-dissolving tablets, and combination pediatric formulations. Patent filings related to delivery mechanisms extend exclusivity.

3. How significant is online sales for this market segment?
Online sales represent about 15% of pediatric analgesic sales and are expected to comprise 25% by 2030, driven by consumer convenience and direct-to-consumer marketing.

4. What regulatory trends could impact Junior Strength Motrin?
Potential updates include stricter dosing guidelines and safety warnings. FDA's pediatric labeling review process could influence formulation requirements.

5. How does market growth compare to adult analgesic markets?
Pediatric OTC analgesics grow at a slightly higher CAGR (5.2%) than adult counterparts (~3-4%), reflecting increased healthcare awareness and parental spending.

---

Sources:

[1] Grand View Research, "Pediatric OTC Analgesics Market Size & Trends," 2022.

[2] IMS Health (IQVIA), "OTC Pediatric Analgesics Market Share Report," 2022.

[3] Company Annual Reports, 2012-2022.

[4] NielsenIQ, "E-commerce Trends in OTC Healthcare," 2022.